A 63-year-old woman presented with a complaint of left buttock mass that had rapidly increased in size after a recent trauma. The patient was otherwise asymptomatic, denying any pain or constitutional symptoms. On physical exam, a well-defined, firm, freely mobile 20-cm mass with intact, non-erythematous overlying skin was palpated in the medial-lower quadrant of the left buttock, contiguous to the left perineal region. On digital rectal examination, the mass was palpable on left posterior aspect of the rectal wall, with smooth and intact overlying mucosa.
. MRI of the pelvis showing a large mass occupying the left ischiorectal fossa. Pathology examination revealed a 14 x 12 x 7-cm well-encapsulated neoplasm characterized by a proliferation of spindleshaped and oval cells, demonstrating a variety of growth patterns consistent with solitary fibrous tumor (SFT). The tumor showed intense immunohistochemical positivity for vimentin and CD34 (Figure 3 ). The expression of vimentin and CD34 differentiates SFT from leiomyosarcoma, fibrosarcoma, carcinosarcoma, phylloides tumor, and hemangiopericytoma. Other makers commonly expressed are Bcl-2 and CD99. [1] [2] [3] SFTs are rare neoplasms of the soft tissue, most commonly arising in the pleura, although several case reports have described extrathoracic locations. [2] [3] MRI is the imaging modality of choice, accurately identifying these lesions based on peculiar radiological features suggestive of fibrosis, predominantly at the core of the lesion (Figure 1 ).
Complete surgical resection is the only curative treatment. The role of radiotherapy and chemotherapy is uncertain and further studies are needed. It has been reported that 10-15% of SFTs are malignant; however, histological findings cannot always predict clinical behavior. Size greater than 10 cm and high cellularity with crowded or overlapping nuclei, high mitotic activity, nuclear pleomorphism, and necrosis are considered to be associated with malignant behavior. Careful long-term follow-up is recommended after surgery. 4 Although the clinical experience with this tumor is limited, we elected to follow the patient with annual MRI for at least 10 years.
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